Bristol-Myers Squibb (BMY) announced Thursday morning that a Phase 3 study of Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma met its co-primary endpoint, demonstrating superior overall survival compared to sunitinib in intermediate- and poor-risk patients.
from RTT - Before the Bell http://ift.tt/2vStEAe
via IFTTT
No comments:
Post a Comment